29th week of 2009 patent applcation highlights part 20 |
Patent application number | Title | Published |
20090181968 | Novel 3-Bicyclocarbonylaminopyridine-2-Carboxamides or 3-Bicyclocarbonylaminopyrazine-2-Carboxamides - The present invention relates to compounds of formula (I) [Chemical formula should be inserted here. Please see paper copy] as well as pharmaceutically acceptable salts and pharmaceutical compositions including the compounds are prepared or thereof: wherein, A | 2009-07-16 |
20090181969 | Hypotensive Lipid And Timolol Compositions And Methods Of Using Same - New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension. | 2009-07-16 |
20090181970 | Functionalized diarylisoxazoles inhibitors of ciclooxygenase - The present invention refers to isoxazole derivatives, in particular diarylisoxazole derivatives inhibitors of cyclooxygenase (COX), in particular cyclooxygenase-1 (COX-1), to their pharmaceutical compositions, the process for their preparation and their use for the chemoprevention and treatment of inflammatory syndromes and in the prevention and treatment of carcinomas, in particular intestinal, ovarian and cutaneous carcinomas, in the treatment of pain syndromes, in particular after surgery, and in the cardiovascular field as antithrombotics/vasoprotectives/cardioprotectives. | 2009-07-16 |
20090181971 | Inhibitors of Histone Deacetylase - The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions. | 2009-07-16 |
20090181972 | Novel Inhibitors of Cysteine Proteases, the Pharmaceutical Compositions Thereof and their Therapeutic Applications - The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use. | 2009-07-16 |
20090181973 | Medicinal composition comprising 3-alkoxy-6-allylthiopyridazines for prevention or treatment of cancer of the pancreas - The present invention relates to a medicinal composition for preventing or treating pancreatic cancer, comprising 3-alkoxy-6-allylthiopyridazine or a pharmaceutically acceptable salt thereof as an effective ingredient. An MTT assay, to assess the viability of cells, and flow cytometric analysis, to measure apoptotic cell death, were performed, and the results, which revealed that the compound and pharmaceutically acceptable salts thereof have preventive and therapeutic activity against pancreatic cancer, are presented herein. | 2009-07-16 |
20090181974 | Composition for slowing down the development of alzheimer's disease - The invention relates to a composition comprising: vegetable oil containing at least one linoleic acid and at least one linolenic acid, vitamin E, and vitamin B9 (or folates), whereby the linoleic acid/linolenic acid weight ratio is between 3 and 5. The inventive composition is intended to slow down the development of Alzheimer's disease and to improve the patient's quality of life. Said composition is intended to be incorporated in a vector that can be assimilated by the human body, preferably by means of dietary intake. | 2009-07-16 |
20090181976 | Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome - The present invention refers to the use of compounds binding to the sigma receptor for the treatment of metabolic syndrome. | 2009-07-16 |
20090181977 | Anhydrous Amorphous Imatinib Mesylate - Described is a highly stable amorphous form of imatinib mesylate having a water content of less than 0.5 percent by weight, based on the total weight of the amorphous imatinib mesylate, (anhydrous amorphous imatinib mesylate), a process for preparation thereof, and pharmaceutical compositions. | 2009-07-16 |
20090181978 | 5-HT1A RECEPTOR SUBTYPE AGONIST - The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT | 2009-07-16 |
20090181979 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES - A lacate salt of a compound of Formula I or a tautomer of the compound, wherein Formula I has the following structure and R | 2009-07-16 |
20090181980 | Synergistic Pharmaceutical Composition - A therapeutic agent for administration to a bacterium or to the environment thereof which agent comprises synergistically effective amounts of (i) an RNA polymerase inhibitor and (ii) an ALS enzyme inhibitor. | 2009-07-16 |
20090181981 | CRYSTALLINE (R)-2-(4-CYCLOPROPANESULPHONYL-PHENYL)-N-PYRAZIN-2-YL-3-(TETRAHYDROPYRAN-- 4-YL)-PROPIONAMIDE - Crystalline R-2-(4-cyclopropanesulfonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide and methods of its preparation and use are disclosed. | 2009-07-16 |
20090181982 | SUBSTITUTED PYRROLINE KINASE INHIBITORS - The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder. | 2009-07-16 |
20090181993 | HIV INHIBITING 5-HETEROCYCLYL PYRIMIDINES - HIV replication inhibitors of formula (I), N-oxides, pharmaceutically acceptable addition salts, quaternary amines or stereoisomeric forms thereof, wherein -a | 2009-07-16 |
20090181994 | TRIAZOLE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1 - Triazole derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other symptoms associated with NIDDM. | 2009-07-16 |
20090181995 | 2-ANILINO-4-AMINOALKYLENEAMINOPYRIMIDINES - The present invention relates to 2-arylamino-4-(aminoalkylene)aminopyrimidines inhibitors which are inhibitors and therefore inhibit Protein Kinase C-alpha (PKC-α). The PKC-α inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4-(aminoalkylene)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure. | 2009-07-16 |
20090181996 | SUBSTITUTED QUINOLONES III - The invention relates to substituted quinolones and to methods for their preparation as well as to their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially for use as antiviral agents, particularly against cytomegaloviruses. | 2009-07-16 |
20090181997 | THERAPEUTIC CANCER TREATMENTS - The invention is directed to use of hedgehog inhibitors in conjunction with chemotherapy in treating cancers, and preventing relapses thereby. | 2009-07-16 |
20090182000 | STEROIDAL COMPOUNDS AS STEROID SULPHATASE INHIBITORS - There is provided a compound having Formula I | 2009-07-16 |
20090182001 | Inhibitors of checkpoint kinases - The instant invention provides for compounds which comprise fused imidazoles that inhibit CHK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting CHK1 activity by administering the compound to a patient in need of treatment of cancer. | 2009-07-16 |
20090182002 | Tyrosine kinase inhibitors - This invention relates to salt forms of the compound N-[(2R)-1,4-dioxan-2-ylmethyl]-N-methyl-N′-[3-(1-methyl- | 2009-07-16 |
20090182013 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment - The invention relates to new compounds of 5-thioxilose, preferably derivatives of the 5-thioxilopyranose type, and to a method for preparing the same and their use as the active ingredient of drugs mainly intended for treating or inhibiting thrombosis or heart failure or thromboembolic diseases. | 2009-07-16 |
20090182014 | INSECTICIDAL COMPOSITIONS COMPRISING COMPOUNDS HAVING INHIBITORY ACTIVITY VERSUS ACYL COA: CHOLESTEROL ACYLTRANSFERASE OR SALTS THEREOF AS EFFECTIVE INGREDIENTS - The present invention relates to insecticidal compositions comprising compounds having an inhibitory activity versus acyl CoA: cholesterol acyltransferase (ACAT) or salts thereof as effective ingredients. The compounds having inhibitory activity versus ACAT have an excellent insecticidal effect by inhibiting sterol metabolism in noxious insects. Therefore, the compounds of the present invention can be used as safe and effective insecticides. | 2009-07-16 |
20090182015 | MICROCAPSULE FORMULATIONS - A method of producing microcapsule formulations wherein slurries containing imidacloprid suspended in water-immiscible organic solvents are wet-crushed, then, urethane-based macromolecular polymers are added to this, and the resultant mixture is dispersed as liquid drops in water, to form membranes on the interfaces of the liquid drops. | 2009-07-16 |
20090182016 | OPTICAL ENANTIOMERS OF PHENYRAMIDOL AND PROCESS FOR CHIRAL SYNTHESIS - The present invention discloses optically pure (R) and (S) Phenyramidol enantiomers and their pharmaceutically acceptable salts, a process for synthesising such enantiomers by means of a styrene oxide based asymmetric synthesis, and also a clinical evaluation of (R) and (S) enantiomers of Phenyramidol, their salts and compositions thereof for enhanced/newer therapeutic benefits. | 2009-07-16 |
20090182017 | Pre-Mixed, Ready-To-Use Pharmaceutical Compositions - Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions. | 2009-07-16 |
20090182018 | Pre-Mixed, Ready-To-Use Pharmaceutical Compositions - Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions. | 2009-07-16 |
20090182019 | Histone deacetylase inhibitors - The present invention provides novel HDAC inhibitors and methods of treating diseases using the same. | 2009-07-16 |
20090182020 | SUBSTITUTED BIS(HETERO)AROMATIC N--ETHYLPROPIOLAMIDES AND USE THEREOF FOR PRODUCTION OF MEDICAMENTS - The present invention relates to substituted bis(hetero)aromatic N-ethylpropiolamides, methods for the production thereof, medicaments containing these compounds and the use thereof for the production of medicaments. | 2009-07-16 |
20090182021 | Tricyclic Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease - The present invention is directed to tricyclic compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved. | 2009-07-16 |
20090182022 | Treatment of Fatty Liver - Methods and compositions comprising peroxisomal and/or mitochondrial beta oxidation stimulating agents to reverse or resolve, slow the progression of, treat or prevent the development of fatty liver and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure. An active agent that by itself is associated with an increased risk of fatty liver development and conditions stemming from fatty liver, such as NASH, liver inflammation, cirrhosis and liver failure, may be administered in combination with peroxisomal and/or mitochondrial beta oxidation stimulating agents. A combination regimen involving such agents, as simultaneous or concomitant therapy, or as a fixed dosage form, is also provided. | 2009-07-16 |
20090182043 | Pharmaceutical Preparation of Aqueous Solution Containing Platinum Complex - To provide an aqueous pharmaceutical preparation of a platinum complex which has no fear of contaminating a compounder with a drug with cytotoxicity, can be prepared by a simple operation, has a compact size, and is suppressed from deteriorating of drug during a long-term storage, an aqueous pharmaceutical preparation of a solution of a platinum complex in a stable state, in which an aqueous solution containing a platinum complex is contained in an oxygen-permeable container, and the oxygen-permeable container is contained in an oxygen-barrier container, the preparation being characterized in that the gap between the oxygen-barrier container and the oxygen-permeable container is filled with gas containing oxygen. | 2009-07-16 |
20090182044 | NITRATE AMINO ACID CHELATES - The present invention is directed to methods and compositions which include nitrate amino acid chelates that can increase the metabolic activity or metal concentration in animals and that can increase metabolic activity and nitrogen content in plants. In one embodiment, a nitrate-complexed amino acid composition can comprise a metal, an amino acid ligand, and a nitrate, wherein the amino acid ligand is chelated to the metal forming an amino acid chelate and the nitrate is complexed to the amino acid chelate. In another embodiment, a nitrate-chelated amino acid composition can comprise a metal, an amino acid ligand, and a nitrate, wherein the amino acid ligand and the nitrate are chelated to the metal forming a nitrate-chelated amino acid chelate. | 2009-07-16 |
20090182045 | USE OF AMINAPHTONE FOR THE PREPARATION OF A MEDICAMENT FOR TREATING ARTERIOPATHIES - The subject of the present invention is the use of aminaphtone for the preparation of a medicament for treating arteriophaties, in particular arteriophaties of a degenerative inflammatory type. Preferably, said medicament is formulated for oral administration. | 2009-07-16 |
20090182046 | Cosmetic Compositions Containing Esters Based on 2-Propylheptanol - Esters of 2-propylheptanol with linear or branched, saturated or unsaturated C | 2009-07-16 |
20090182047 | UTILIZATION OF DIALKYLFUMARATES - The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in combination with conventional preparations used in transplantation medicine and immunosuppressive agents, especially cyclosporines. | 2009-07-16 |
20090182048 | Compounds Useful For Treating Neurological Disorders - The invention relates to the use of compounds for the preparation of a medicament for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. The invention additionally relates to a pharmaceutical composition comprising compounds for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration. A method for treating neuropathic pain, migraine, psychiatric disorder and/or neuronal degeneration is also provided. | 2009-07-16 |
20090182049 | Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans - A method for the treatment or prophylaxis of hypertriglyceridemia and hypercholesterolemia without concomitantly increasing LDL-serum cholesterol, in a human subject requiring such treatment, which method comprises orally administering to the patient an effective amount of a pharmaceutical composition in which the active ingredients comprise a mixture of fatty acids, wherein said mixture comprises at least about 60% by weight a combination of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from about 1.4:1 to about 5:1, wherein said combination is at least about 60% in the triglyceride form of the fatty acids and the balance is at least about 80% of mono and di-glycerides. | 2009-07-16 |
20090182050 | Salts of Fatty Acids and Methods of Making and Using thereof - Disclosed are methods of making salts of fatty acids (e.g., marine oils) and to salts prepared by the disclosed methods. Methods of using the disclosed salts are also disclosed. | 2009-07-16 |
20090182051 | COSMECEUTICAL FORMULATION CONTAINING PALM OILS - A cosmeceutical formulation is provided that includes a mixture of a refined, bleached, deodorized (RBD) palm oils and red palm olein. The resulting formulation is a homogeneous blend with a considerable shelf life. The formulation may be a cream, lotion, sunscreen, or a soap and may be formulated to include additional beneficial oils and EFAs. If a cream formulation is desired, RBD palm stearin is the preferred palm oil for producing a creamy texture. If a lotion is desired, RBD palm oil may be used and chemically modified to produce a tailored oil with a desired melting point and consistency. The formulation may be used to treat a variety of skin conditions including adverse and age-related skin conditions or as an effective moisturizer for the prolonged maintenance of ordinary skin. | 2009-07-16 |
20090182052 | TASTE-MASKED DOCUSATE COMPOSITIONS - A taste-masked liquid composition of docusate includes a docusate salt, povidone, a polyether, and water. Additional ingredients in the composition may include thickeners, sweeteners, flavorants, polyols, preservatives, chelating agents and pH adjusters. Such compositions may be used as taste-masked oral compositions of docusate, and may provide therapeutic effects such as stool-softening. | 2009-07-16 |
20090182063 | RGD-ENRICHED GELATINE-LIKE PROTEINS WITH ENHANCED CELL BINDING - The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at least 0.4 and if the RGD-enriched gelatine comprises 350 amino acids or more, each stretch of 350 amino acids contains at least one RGD motif. Preferably the RGD-enriched gelatines are prepared by recombinant technology, and have a sequence that is derived from a human gelatine or collagen amino acid sequence. The invention also relates to RGD-enriched gelatines that are used for attachment to integrins. In particular The RGD-enriched gelatines of the invention are suitable for coating a cell culture support for growing anchor-dependant cell types. Further, the RGD-enriched gelatines of the invention may find use in medical applications, in particular as a coating on implant or transplant material or as a component of drug delivery systems. | 2009-07-16 |
20090182064 | Reactive Separation To Upgrade Bioprocess Intermediates To Higher Value Liquid Fuels or Chemicals - The process and system of the embodiments utilize a reactive separation unit to upgrade a bioprocess intermediate stream to higher value liquid fuels or chemicals. The reactive separation unit simultaneously enables molecular weight and density increases, oxygen content reduction, efficient process energy integration, optional water separation for potential reuse, and incorporation of additional hydrocarbons or oxygenated hydrocarbons as co-feed(s). The use and selection of particular co-feed(s) for this purpose enables tailoring of the intended product composition. The process and system yields a product of higher alcohols, liquid hydrocarbons, or a combination of these. These can be split into two (or more) boiling point fractions by the same reactive separations unit operation resulting in product(s) that can be used as chemicals, chemical intermediates, or alternative (non-fossil-based) liquid transportation fuels. | 2009-07-16 |
20090182065 | PROCESS FOR PRODUCING CONDUCTIVE RUBBER ROLLER, AND ROLLER FOR ELECTROPHOTOGRAPHIC APPARATUS - This invention provides a process for producing a conductive rubber roller having small aspect ratios of inner and outer diameters, having a stable measure of its inner diameter, having uniform cell distribution and being free from non-uniformity of hardness and electrical resistance in the peripheral direction. The process has a step of continuously extruding a tube composed of a specific unvulcanized rubber composition from a rubber extruder in a microwave vulcanizing unit, and a step of foaming and vulcanizing the tube by using a microwave irradiator having a microwave irradiation zone 4 m or less in length while being transported at given speed. The foamed rubber tube has an inner diameter 20 to 35% smaller than the outer diameter of the conductive core material over the whole region in the lengthwise direction, and the conductive core material is press-fitted into the foamed rubber tube without using any adhesive. | 2009-07-16 |
20090182066 | CROSSLINKABLE FLUOROPOLYMER, CROSSLINKED FLUOROPOLYMERS AND CROSSLINKED FLUOROPOLYMER MEMBRANES - Crosslinkable polymers and crosslinked fluoropolymers are prepared from selected fluorinated dienes and monomers containing Br and I. Also disclosed are proton conductive membranes of these crosslinked fluoropolymers. | 2009-07-16 |
20090182067 | Polymerizable Contact Lens Formulations and Contact Lenses Obtained Therefrom - Contact lenses, such as hydrogel contact lenses, are described. The present contact lenses include a lens body that is the reaction product of a polymerizable composition. The polymerizable composition includes one or more monomers and a crosslinker that crosslinks the one or more monomers during polymerization. The polymerization of the one or more monomers occurs in the presence of a hydrophilic polymer that is present in the polymerizable composition, which comprises a polymer of 2-methacryloyloxyethyl phosphorylcholine. The present lenses are capable of releasing the hydrophilic polymer from the contact lens for prolonged periods of time and also have a reduced surface friction compared to similar lenses without the hydrophilic polymer. The present invention also relates to packaging systems for use with such lenses and methods of producing such lenses. | 2009-07-16 |
20090182068 | Polymerizable Contact Lens Formulations and Contact Lenses Obtained Therefrom - Contact lenses, such as hydrogel contact lenses, are described. The present contact lenses include a lens body that is the reaction product of a polymerizable composition. The polymerizable composition includes one or more monomers and a crosslinker that crosslinks the one or more monomers during polymerization. The polymerization of the one or more monomers occurs in the presence of at least two forms of polyvinyl pyrrolidone, each of the at least two forms of polyvinyl pyrrolidone having a different average molecular weight. The at least two forms of polyvinyl pyrrolidone are associated with the first polymer component in the lens body such that a form of polyvinyl pyrrolidone is released from the lens body for at least eight hours based on in vitro release testing. The present invention also relates to packaging systems for use with such lenses and methods of producing such lenses. | 2009-07-16 |
20090182069 | RUBBER COMPOSITION CONTAINING MODIFIED CONJUGATED DIENE-BASED POLYMER BONDED TO FULLERENE - A rubber composition obtained by compounding thereinto a rubber component containing 0.5 to 100% by weight of a modified conjugated diene-based polymer having a fullerene bonded thereto in the molecule and having a weight average molecular weight of 50,000 or more excellent processability, superior balance of modulus and heat buildup, excellent cold flowability and superior tan δ balance. | 2009-07-16 |
20090182070 | POLYESTER FIBER AND TEXTILE PRODUCT COMPRISING THE SAME - Polyester fibers comprising a polyester resin composition which contains carbon black and comprises trimethylene terephthalate units as the main repeating structural units, and having an average resistivity (P) of 1.0×10 | 2009-07-16 |
20090182071 | Wood composite alloy composition having a compatibilizer that improves the ability to process and compress cellulosic fiber - A crystalline polyamide 6 in a compounding extrusion process to make wood flour-polyolefin composite. The wood plastic composite pellet and can be post-blended with reinforced polyolefin pellets in an injection molding step to produce hybrid fibrous composites. The resulting compatibilization in the hybrid fibrous composites gives molded parts having enhanced mechanical properties at greatly reduced temperatures. There is wide variety of molded parts that can be made by varying the blend ratio of the wood plastic compounded product with or without and glass fiber reinforced pellets in the injection molding step. | 2009-07-16 |
20090182072 | Use of Zinc Oxide to Improve Compatibility of Polymer Modified Asphalt Crosslinked with Phenol Aldenyde Resin - In methods of preparing asphalt and elastomeric polymer compositions crosslinked with phenol aldehyde resins and sulfur, such as polymer modified asphalt (PMA), it has been discovered that the MP1 compatibility may be improved by adding certain ionic metal salts. Suitable ionic metal oxides include, but are not necessarily limited to, zinc oxide, cadmium oxide, and the like. Acceptable elastomeric polymers include, but are not necessarily limited to, styrene-butadiene copolymers. Additional sulfur-containing crosslinkers may also be used. | 2009-07-16 |
20090182083 | METAL COATING COMPOSITION - The present invention provides for a resin system and coating composition suitable for direct application to metal substrates. The composition may include a phosphate functional polyester. The polyester may be an unsaturated polyester polyol. The coating composition may further include a suitable curing agent, such as an isocyanate or melamine. The composition can be applied through traditional application equipment onto a variety of metal substrates and cures to an acceptable surface for further processing, such as top coating with basecoat and clearcoat. | 2009-07-16 |
20090182084 | METAL COATING COMPOSITION - The present invention provides for a metal coating composition that includes a resin system with at least one unsaturated polyester polyol and a curing agent such as an isocyanate or a melamine. The compositions are suitable as a primer and provide good adhesion and moisture resistance to metal substrates. | 2009-07-16 |
20090182085 | POLYURETHANE-BASED RETENTION, COVERING, FILLING AND REINFORCEMENT COMPOSITION - The present invention is related to the usage of a composition of polyurethanes to obtain adequate materials for retention, resistance, reinforcement, covering and sealing of geological and architectonical structures, including the common used building materials such as brick, concrete, masonry, partition wall, clay, among others. | 2009-07-16 |
20090182086 | POLYAMIDE RESIN COMPOSITION - Provided is a polyamide resin composition superior in mechanical properties such as strength and elastic modulus and also in toughness, durability, frictional abrasion resistance, and water absorption resistance. | 2009-07-16 |
20090182087 | NANO-COMPOSITE AND COMPOSITIONS THEREFROM - The present invention relates to various nano-composites and compositions comprising a cationic mediator and method thereof. The cationic mediator comprises a polymeric group and a cationic unit selected from the group consisting of onium cation and heterocyclic cation. The nano-composites and compositions exhibit improved gas permeability property, strong moisture absorbance, and high electrical conductivity etc. | 2009-07-16 |
20090182088 | Composite coatings for groundwall insulation, method of manufacture thereof and articles derived therefrom - Disclosed herein is an article comprising an electrical component; and an electrically insulating layer disposed upon the electrical component, wherein the electrically insulating layer comprises a thermosetting polymer and a nanosized filler; wherein the nanosized filler comprises metal oxide and diamond nanoparticles that have an average largest dimension of less than or equal to about 200 nanometers. | 2009-07-16 |
20090182089 | Golf balls with soft, resilient bimodal ionomeric covers - Disclosed are golf balls having soft, resilient bimodal ionomeric covers with improved softness and scuff resistance and methods for their preparation. The soft, resilient bimodal ionomeric covers comprise at least partially neutralized mixtures of carboxylate functionalized terpolymers (molecular weight between about 80,000 and 500,000) with carboxylate functionalized ethylene low copolymers (molecular weight between about 2,000 and 30,000). | 2009-07-16 |
20090182090 | USE OF CARBOXYL-FUNCTIONAL POLYVINYL ACETATES FOR PRODUCING BMC PARTS - BMC molding compositions containing carboxy-functional polyvinyl acetate resins having minimally 3 weight percent of carboxy-functional monomers exhibit only modest increase in viscosity upon addition of fillers as compared to similar compositions employing polyvinyl acetate homopolymers. | 2009-07-16 |
20090182091 | CURABLE COMPOSITION - The present invention has its object to provide a curable composition which comprises a guanidine compound as a non-organotin type catalyst, is less discolored, has good surface curability, depth curability, strength rise and adhesiveness, and can retain the curability even after storage; the above object can be achieved by a curable composition which comprises: (A) an organic polymer containing a silyl group capable of crosslinking under siloxane bond formation, the silyl group being a group represented by the general formula (1): —SiX | 2009-07-16 |
20090182092 | PROCESS FOR PRODUCTION OF WATER-ABSORBENT RESIN - A purpose of the present invention is to reduce odor of a water-absorbent resin during absorption of water. Such the invention is attained by a process for production of a water-absorbent resin by subjecting a water-soluble ethylenically unsaturated monomer to reversed-phase suspension polymerization. The process comprises the following steps (A) to (C): (A) adding an aqueous solution of water-soluble ethylenically unsaturated monomer to a petroleum hydrocarbon dispersion medium to disperse the aqueous solution in the dispersion medium; (B) adding a surfactant to the emulsion to further disperse the emulsion; and (C) performing the reversed-phase suspension polymerization using a water-soluble radical polymerization initiator, optionally in the presence of an internal-crosslinking agent. | 2009-07-16 |
20090182113 | SEGMENTED POLYURETHANE ELASTOMERS WITH HIGH ELONGATION AT TEAR - The present invention relates to a process for producing a polyurethane elastomer fiber, which comprises a) reacting polymeric diol with a substance reactive therewith to form an OH-terminated prepolymer, b) reacting the OH-terminated prepolymer with a diisocyanate to form an isocyanate-terminated prepolymer, c) reacting the isocyanate-terminated prepolymer with a chain extender, if appropriate a chain-terminating agent and if appropriate further additives to form the polyurethane elastomer, and d) spinning the polyurethane elastomer to form a fiber, in which there are less than 15% by weight of further polyurethane elastomers in the fiber. The present invention further relates to a polyurethane elastomer fiber obtainable by such a process, to its use for producing textiles, for example wovens or knits, and also to the use of a polyurethane elastomer for producing such a fiber. | 2009-07-16 |
20090182114 | TETRACARBOXYLIC ACID COMPOUND, POLYIMIDE THEREOF, AND PRODUCTION METHOD THEREOF - Disclosed is a novel tetracarboxylic acid compound having excellent characteristics such as high transparency, low dielectric property, low water absorption, low thermal expansion, solvent solubility and etching characteristics, while exhibiting high heat resistance at the same time. This tetracarboxylic acid compound is useful as a raw material monomer for producing a polyesterimide or a polyamideimide. Specifically disclosed is a tetracarboxylic acid compound represented by the general formula (1) or (2) below. | 2009-07-16 |
20090182115 | POLYAMIC ACID AND POLYIMIDE - Disclosed are a polyamic acid containing not less than 10 mol % of a repeating unit represented by the formula [1] below, and a polyimide represented by the formula [2] below which is obtained from such a polyamic acid. The polyamic acid and polyimide have high heat resistance as shown by a thermal decomposition temperature of not less than 300° C. In addition, the polyamic acid and polyimide have good workability because of their high solubility in solvents, while exhibiting good light transmission. (In the formulae, R | 2009-07-16 |
20090182116 | MANUFACTURE OF PHOSPHORUS-CONTAINING DIAMINES AND THEIR DERIVATIVES - A series of novel phosphorus-containing compounds having the following formula are disclosed: | 2009-07-16 |
20090182117 | STRETCHED FILM OF ADDITION POLYMER CONSISTING OF NORBORNENE COMPOUND, PROCESS FOR PRODUCING THE SAME AND USE THEREOF - [Problems] To provide a stretched film of an addition polymer consisting of norbornene compounds favorable for use in manufacturing steps of electric insulating parts and optical parts that exhibits excellent film stability, does not suffer from coloration and has a low linear expansion coefficient. | 2009-07-16 |
20090182118 | METHOD FOR PRODUCING POLYGUANIDINES - The invention relates to polyguanidine synthesis. The inventive method for producing polyguanidines consists in polycondensing a guanidine salt with diamine during heating in the presence of an organic acid or a mixture of organic acids. A heating process is carried out stepped process and consists in gradually increasing a temperature up to 120-130° C. and in holding at said temperature for 0.5-1.0 hour, in increasing a temperature up to 150-160° C. and in holding at said temperature for 3.5-4.0 hours and in increasing a temperature up to 170-180° C. and in holding at said temperature for 1.0-1.5 hours. Said method makes it possible obtain, in a more full manner and in shorter time, a polyguanidine, which exhibits a high biological activity. The thus obtained polyguanidines are not toxic and can be efficiently used for treating drinking and sewage waters and for producing antiseptic, cosmetic and disinfecting agents. | 2009-07-16 |
20090182119 | CATALYTICALLY ACTIVE PEPTIDES - A catalytically active peptide comprising an imidazole function in position i flanked by at least one functional group to be amidated in position i+3+4k, where k is an integer equal to or higher than −1 or in position i−4−4n, wherein n is an integer equal to or higher than 0, characterized in that it also comprises at least one activating group in position i+4+4n or i−3−4n, respectively, wherein n is as above. | 2009-07-16 |
20090182120 | SURFACE MEDIATED SELF-ASSEMBLY OF NANOPARTICLES - Materials and methods for surface mediated self assembly of nanoparticles for the isolation of biomolecules is provided. | 2009-07-16 |
20090182121 | Regulation of Human Transmembrane Serine Protease - Reagents that regulate human transmembrane serine protease activity and reagents that bind to human transmembrane serine protease gene products can be used to regulate extracellular matrix degradation. Such regulation is particularly useful for treating COPD, metastasis of malignant cells, tumor angiogenesis, inflammation, atherosclerosis, neurodegenerative diseases, and pathogenic infections. | 2009-07-16 |
20090182122 | NUCLEIC ACID SEQUENCES ENCODING TRANSCRIPTION FACTOR PROTEINS - Isolated polynucleotides and polypeptides encoded thereby are described, together with the use of those products for making transgenic plants. | 2009-07-16 |
20090182123 | Method of Preparing Botulinum Neurotoxin Type E Light Chain - The present invention provides a preparation of botulinum toxin light chain type A or E, wherein the preparation is both catalytically active and soluble. Preferably, the preparation consists essentially of amino acid residues 1 through 425 of the botulinum toxin light chain type A. A method of screening inhibitors is also provided, wherein the method comprises exposing a test inhibitor to the preparation of botulinum toxin light chain type A and evaluating the biological activity of the preparation. In another embodiment, a method of providing a catalytically active, soluble preparation of botulinum toxin light chain, type A is provided, wherein the method comprises obtaining an expression vector comprising a DNA sequence encoding amino acid residues 1-425 and expressing a polypeptide. | 2009-07-16 |
20090182124 | NOVEL TRANSCRIPTION FACTOR HAVING ZINC FINGER DOMAINS - Using an undifferentiated mouse CL6 cell line, DMSO was added to induce its differentiation into cardiac muscular cells in order to obtain gene fragments whose expression elevated upon the induction. The isolated gene had zinc finger domains and showed a significant homology to the Sp1 family genes. Furthermore, a human gene corresponding to this mouse gene was isolated. The protein encoded by this gene existed in the nucleus and bonded to a GC-box. The protein was revealed to repress the transcription regulatory activity of the CMV promoter and thus serves as a transcription factor. | 2009-07-16 |
20090182125 | Porphyrin compound, albumin inclusion compound thereof and artificial oxygen carrier - A porphyrin compound represented by general formula (A): | 2009-07-16 |
20090182126 | GUANYLATE-BINDING PROTEIN - A member of the guanylate-binding protein family, designated GBP-4, is provided. Also provided are isolated nucleic acid encoding GBP-4, vectors and host cells containing such nucleic acid molecule, and a method for producing the GBP-4 recombinantly. | 2009-07-16 |
20090182127 | Production of Bispecific Antibodies - Bispecific antibodies comprising (a) a first light-heavy chain pair having specificity for a first target and a sufficient number of substitutions in its heavy chain constant domain with respect to a corresponding wild-type antibody of the same isotype to significantly reduce the formation of first heavy chain-first heavy chain dimers and (b) a second light-heavy chain pair comprising a heavy chain having a sequence that is complementary to the sequence of the first pair heavy chain sequence with respect to the formation of intramolecular ionic interactions, wherein the first pair or second pair comprises a substitution in the light chain and complementary substitution in the heavy chain that reduces the ability of the light chain to interact with the heavy chain of the other light chain-heavy chain pair are provided. Methods of producing such antibodies in one or more cells also are provided. | 2009-07-16 |
20090182128 | Capsular Polysaccharide Solubilisation and Combination Vaccines - Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1. | 2009-07-16 |
20090182129 | Capsular Polysaccharide Solubilisation and Combination Vaccines - Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The material obtained, preferably following hydrolysis and sizing, can be conjugated to a carrier protein and formulated as a vaccine. Also, in vaccines comprising saccharides from both serogroups A and C, the invention provides that the ratio (w/w) of MenA saccharide:MenC saccharide is >1. | 2009-07-16 |
20090182130 | Methods of protein production using ovomucoid promoters - Methods of producing protein using a recombinant ovomucoid gene expression controlling region operably linked to one or more useful amino acid coding sequences. | 2009-07-16 |
20090182131 | Methods for removing anti-MHC antibodies from a sample - The present invention relates generally to anti-MHC assay methodologies utilizing functionally active, recombinantly produced, and truncated individual soluble MHC trimolecular complexes that are linked to a substrate. The methods include reacting a sample with the substrate having the MHC trimolecular complex linked thereto, whereby antibodies specific for the at least one MHC trimolecular complex linked to the substrate are removed from the biological sample. | 2009-07-16 |
20090182132 | RECTANGULAR PARALLELEPIPEDAL MALTITOL - The invention concerns maltitol crystals, characterized in that they have a rectangular parallelepipedal shape and have a length to width dimensional ratio in the range 1.8 to 5.3, preferably 3±0.7, and a process for producing them. | 2009-07-16 |
20090182143 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - The present invention relates to novel heterocyclic compounds, their analogs, their tautomers, their regioisomers, their stereoisomers, their enantiomers, their diastereomers, their polymorphs, their pharmaceutically acceptable salts, their appropriate N-oxides, their pharmaceutically acceptable solvates and their pharmaceutical compositions containing them. The present invention more particularly relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the Formula (1), their analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxide, pharmaceutically acceptable solvates and the pharmaceutical compositions containing them. | 2009-07-16 |
20090182144 | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE - The present invention aims to provide compounds which have an inhibitory effect on the binding between S1P and its receptor Edg-1(S1P | 2009-07-16 |
20090182145 | PROCESS FOR PREPARING CARBOXYLIC ACID DERIVATIVES - The present invention relates to processes for preparing carboxylic acid derivatives, comprising the reaction of at least one carboxylic acid and/or of a carboxylic acid derivative with at least one alcohol and/or an amine in the presence of a metal-containing catalyst, wherein, after the reaction has ended, the metal-containing catalyst is contacted with water and a superabsorbent, the contacting of the catalyst with the water leading to hydrolysis of the catalyst. The present invention further relates to the use of superabsorbents for removing a metal-containing catalyst from a mixture after hydrolysis of the catalyst. | 2009-07-16 |
20090182146 | Process for the preparation and purification of cis-2-methylspiro(1,3-oxathiolane-5,3')quiniclidine hydrochloride - An industrially acceptable process for the preparation and purification of cis-2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine from a cisitrans mixture of isomers. Treatment of the mixture with an organic sulfonice acid generates a less soluble acid addition salt that is enriched in the cis-isomer. Recrystallization or pulping using various organic solvents allows for enrichment of the cis-isomer by filtration. These new sulfonic acid salts of the cis-isomer of 2-methylspiro(1,3-oxathiolane-5,3′)quiniclidine prepared according to the present invention could be further converted into the hydrochloride salt by any known procedures such as treatment with a base and then hydrochloric acid salt formation or exchange of the sulfonic acid salt with hydrochloric acid. | 2009-07-16 |
20090182147 | PROCESS FOR THE PREPARATION OF PURE RISEDRONIC ACID OR SALTS - The present invention relates to an industrially advantageous process of making bisphosphonic acid or its salt in particular risedronic acid, [1-hydroxy-2(3-pyridinyl)ethylidene]bisphosphonic acid, having formula-(I) or its salts in high purity and high yields. | 2009-07-16 |
20090182148 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM - An improved process for the manufacture of 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropane acetic acid, sodium salt [montelukast sodium(I)]. It consists of converting a vital intermediate 1-(mercaptomethyl)-cyclopropane acetic acid of formula IX, to a quaternary ammonium salt of formula X, using a suitable base in a suitable solvent at 0° C. to 50° C. followed by monometalation to provide an intermediate of formula XI and subsequent condensation of XI with 2-[2-[3-(S)-[3-[2-(7-chloro-2-quinolinyl)-ethenyl]phenyl]-3-methanesulphonyloxypropyl]phenyl]-2-propanol at 0 to −50° C. to afford 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropane acetic acid as the quaternary ammonium salt which is filtered, purified by crystallization from a suitable solvent and finally treated with a sodium base in a suitable solvent to generate montelukast sodium which is isolated by trituration with an antisolvent. The invention provides a convenient process for preparing montelukast sodium (I) in good yields and purities. | 2009-07-16 |
20090182149 | SALT OF SULFINYLBENZIMIDAZOLE COMPOUND, AND CRYSTAL AND AMORPHOUS FORM THEREOF - Salts of 2-[({4-[(2,2-dimethyl-1,3-dioxan-5-yl)methoxy]-3,5-dimethylpyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole and their crystalline and amorphous forms. | 2009-07-16 |
20090182150 | Novel Intermediate for the Preparation of Paliperidone - A new compound of formula (IV) | 2009-07-16 |
20090182151 | Method for making amphiphilic dendrimers - A series of AB-type amphiphilic dendritic polyesters have been prepared divergently, in which two hybrids were coupled via the copper(1)-catalyzed triazole formation. | 2009-07-16 |
20090182152 | Colorant Compounds - Disclosed is a compound of the formula | 2009-07-16 |
20090182163 | PROCESS FOR MAKING AND REFINING 3-PENTENENITRILE, AND FOR REFINING 2-METHYL-3-BUTENENITRILE - The invention provides an integrated, continuous process for the production of 3-pentenenitrile, the refining of 3-pentenenitrile, and the refining of 2-methyl-3-butenenitrile, the process comprising:
| 2009-07-16 |
20090182164 | HYDROCYANATION OF PENTENENITRILES - The invention provides a hydrocyanation process to produce adiponitrile and other dinitriles having six carbon atoms, in the presence of catalyst composition comprising a zero-valent nickel and at least one bidentate phosphorus-containing ligand wherein the bidentate phosphorus-containing ligand gives acceptable results according to at least one protocol of the 2-Pentenenitrile Hydrocyanation Test Method. | 2009-07-16 |
20090182165 | Process for the Preparation of Carbonylation Products - Process for preparing a carboxylic acid and/or ester thereof by carbonylating an alcohol and/or reactive derivative thereof with carbon monoxide in the presence of a silver loaded mordenite catalyst. | 2009-07-16 |
20090182166 | Method for production of short chain carboxylic acids and esters from biomass and product of same - A method for producing a mixture of short chain carboxylic acids from biomass includes adding biomass to a reactor vessel, heating the biomass to crack it, removing undesired and unreacted materials and light ends from the cracked biomass, and removing a mixture containing carboxylic acids having carbon chain lengths between C2 and C16. A composition includes a carboxyl group-containing compound derived by cracking biomass and having a carboxyl carbon chain length between C2 and C16. | 2009-07-16 |
20090182167 | PROCESS FOR PREPARING ALPHA-HYDROXYCARBOXYLIC ESTERS - Continuous process for preparing alpha-hydroxycarboxylic esters, in which the reactants reacted are alpha-hydroxycarboxamide with an alcohol in the presence of a catalyst to obtain a product mixture which comprises alpha-hydroxycarboxylic ester, ammonia, unconverted alpha-hydroxycarboxamide and alcohol, and catalyst; wherein
| 2009-07-16 |
20090182168 | PROCESS FOR THE SELECTIVE DEPROTONATION AND FUNCTIONALIZATION OF 1-FLUORO-2-SUBSTITUTED-3-CHLOROBENZENES - 1-Fluoro-2-substituted-3-chlorobenzenes are selectively deprotonated and functionalized in the position adjacent to the fluoro substituent. | 2009-07-16 |
20090182169 | METHOD OF CRYSTALLIZATION - The present invention relates to a multi-stage crystallization process which comprises the steps of feeding a solution of terephthalic acid or a slurry (raw slurry) containing terephthalic acid partially precipitated to a first crystallization vessel to precipitate the terephthalic acid therein; and feeding a slurry (crystallization slurry) containing the thus precipitated terephthalic acid sequentially to second and subsequent crystallization vessels, wherein while continuously supplying a cleaning solvent to a delivery conduit connecting the former-stage crystallization vessel and the next latter-stage crystallization vessel to each other, the crystallization slurry is fed through the delivery conduit. There is provided a multi-stage crystallization process using a solution of terephthalic acid or a slurry containing terephthalic acid partially precipitated as a raw material in which even when the process is operated for a period as long as several months, the delivery conduit is free from occurrence of clogging. | 2009-07-16 |
20090182170 | PROCESS FOR PRODUCING ALPHA, BETA-UNSATURATED CARBOXYLIC ACID - Disclosed is a method for enhancing a yield of an α,β-unsaturated carboxylic acid obtained by liquid-phase oxidation reaction of an olefin or an α,β-unsaturated aldehyde. In particular, there is provided a method for producing an α,β-unsaturated carboxylic acid, wherein the method includes the step of carrying out oxidation reaction of an olefin or an α,β-unsaturated aldehyde in a liquid phase to obtain a reaction mixture containing an α,β-unsaturated carboxylic acid and an α,β-unsaturated carboxylic acid anhydride and the step of bringing the α,β-unsaturated carboxylic acid anhydride into contact with an alcohol or water to obtain an α,β-unsaturated carboxylic acid resulting from decomposition of the α,β-unsaturated carboxylic acid anhydride. | 2009-07-16 |